Chiou R K
Department of Urologic Surgery, University of Minnesota Hospital and Clinic, Minneapolis.
J Urol. 1989 Dec;142(6):1584-8. doi: 10.1016/s0022-5347(17)39173-5.
The in vivo localization of renal cell carcinoma-preferential monoclonal antibodies A6H, D5D, and C5H was evaluated and the biodistribution of F(ab')2 antibody fragments of A6H and the intact Mab were compared in over 100 nude mice. A6H localized well to most renal cell carcinoma xenografts studied; the median tumor to blood ratios ranged from 6.4 to 11.5 for various xenografts. C5H also localized well to most renal cell carcinoma xenografts tested. However, D5D did not localize well to renal cell carcinoma xenografts in vivo despite its highly restrictive in vitro reactivity. The F(ab')2 fragments of A6H produced higher tumor to blood ratios, which probably resulted from fast clearance of the fragments from the circulation. Preliminary results showed that indium-111 labeling may further improve imaging.
评估了肾细胞癌优先单克隆抗体A6H、D5D和C5H的体内定位，并比较了A6H的F(ab')2抗体片段和完整单克隆抗体在100多只裸鼠中的生物分布。A6H在大多数研究的肾细胞癌异种移植瘤中定位良好；各种异种移植瘤的肿瘤与血液比值中位数在6.4至11.5之间。C5H在大多数测试的肾细胞癌异种移植瘤中也定位良好。然而，尽管D5D在体外具有高度限制性反应性，但它在体内对肾细胞癌异种移植瘤的定位不佳。A6H的F(ab')2片段产生了更高的肿瘤与血液比值，这可能是由于片段从循环中快速清除所致。初步结果表明，铟-111标记可能会进一步改善成像效果。
